CD33 and acute myeloid leukemia: Figure 6 shows that the effects vorinostat (5 μM/8 h) on the expression of the same panels of genes described above in MDS BM-CD33 cells was comparable to that observed in PB-CD33 cells from AML patients (Figure 5).